(Q33313648)

25 July 2017

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers (English)

1 reference

ORCID Public Data File 2021

25 July 2017

1 reference

1 reference

author name string

Joanna Vermeij

1

1 reference

25 July 2017

Erik Teugels

2

1 reference

25 July 2017

Claire Bourgain

3

1 reference

25 July 2017

Ji Xiangming

4

1 reference

25 July 2017

Peter in 't Veld

5

1 reference

25 July 2017

Vanessa Ghislain

6

1 reference

25 July 2017

Bart Neyns

7

1 reference

25 July 2017

Jacques De Grève

8

1 reference

25 July 2017

language of work or name

English

0 references

publication date

8 January 2008

1 reference

25 July 2017

1 reference

25 July 2017

8

1 reference

25 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-8-3

25 July 2017

0 references

cites work

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Role of the epidermal growth factor network in ovarian follicles.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Erlotinib in previously treated non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

EGF/ErbB receptor family in ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Expression and function of EGF-related peptides and their receptors in gynecological cancer--from basic science to therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2266762

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

A DGGE system for comprehensive mutation screening ofBRCA1andBRCA2: application in a Dutch cancer clinic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-3

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

21 January 2018

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

1 reference

12 December 2020

HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study

1 reference

12 December 2020

Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?

1 reference

12 December 2020

Epithelial growth factor receptor status in primary and recurrent ovarian cancer

1 reference

12 December 2020

Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays

1 reference

12 December 2020

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-8-3

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference